Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe

Background and Objective: Orphan drugs have been a highlight of discussions due to their higher prices than non-orphan drugs. There is currently no European consensus on the method of value assessment for orphan drugs. This study assessed the relationship between the prevalence of rare diseases and...

Descripción completa

Detalles Bibliográficos
Autores principales: Medic, Goran, Korchagina, Daria, Young, Katherine Eve, Toumi, Mondher, Postma, Maarten Jacobus, Wille, Micheline, Hemels, Michiel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Routledge 2017
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5405566/
https://www.ncbi.nlm.nih.gov/pubmed/28473888
http://dx.doi.org/10.1080/20016689.2017.1299665

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5405566/
https://www.ncbi.nlm.nih.gov/pubmed/28473888
http://dx.doi.org/10.1080/20016689.2017.1299665

Ejemplares similares